Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: Final results of the prospective and randomized IFM 99-04 protocol

Blood

Volumn 107, Issue 1, 2006, Pages 397-403

  Moreau, Philippe ^a   Hullin, Cyrille ^b   Garban, Frédéric ^b   Yakoub Agha, Ibrahim ^b   Benboubker, Lotfi ^b   Attal, Michel ^b   Marit, Gérald ^b   Fuzibet, Jean Gabriel ^b   Doyen, Chantal ^b   Voillat, Laurent ^b   Berthou, Christian ^b   Ketterer, Nicolas ^b   Casassus, Philippe ^b   Monconduit, Mathieu ^b   Michallet, Mauricette ^b   Najman, Albert ^b   Sotto, Jean Jacques ^b   Bataille, Régis ^b   Harousseau, Jean Luc ^b  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INTERLEUKIN 6 ANTIBODY; MELPHALAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL TIME;

EID: 30144439125     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2573     Document Type: Article

References (25)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
3. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99:731-735.
4. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
5. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.
6. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive therapy. Blood. 2002;100:1579-1583.
7. Facon T, Avet-Loiseau H, Guillerme G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566-1571.
8. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplantation. Br J Haematol. 2004;125:64-68.
9. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol. 1996;95:527-530.
10. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23:1003-1006.
11. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995;86:685-691.
12. Moreau P, Harousseau JL, Wijdenes J, et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol. 2000;109:661-664.
13. Greipp PR, San Miguel J, Durie BG, et al. The International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
14. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
15. Fassas ABT, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041-1047.
16. Fermand JP, Alberti C, Marolleau JP. Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomised trial in 320 young patients with multiple myeloma [abstract]. Hematol J. 2003;4(suppl 1):S59.
17. Cavo M, Cellini C, Zamagni E, et al. Update on high-dose therapy. Italian studies [abstract]. 10th International Myeloma Workshop, Sydney, Australia. Hematol J. 2005;90(suppl 1):39.
18. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet. 1983;2:822-824.
19. Samuels BJ, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786-1799.
20. 2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma [abstract]. Blood. 2002;100:432a.
21. Rajkumar SV, Hayman S, Gertz M, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
22. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
23. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755-762.
24. Jagannath S, Durie BGM, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776-783.
25. Harousseau JL, Attal M, Coiteux V, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study [abstract]. Proc Am Soc Clin Oncol. 2005;23:598.